Y-Biologics, Inc. (KOSDAQ:338840)
South Korea · Delayed Price · Currency is KRW 13,850
+970 (7.53%)
At close: Sep 12, 2025
Y-Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2020 |
Operating Revenue | - | 5,763 | 3,479 | 4,151 | 4,847 | 6,731 | Upgrade |
Other Revenue | - | - | - | -0 | - | 0 | Upgrade |
| 5,960 | 5,763 | 3,479 | 4,151 | 4,847 | 6,731 | Upgrade | |
Revenue Growth (YoY) | 49.09% | 65.64% | -16.18% | -14.37% | -27.99% | 399.09% | Upgrade |
Cost of Revenue | 1,173 | 1,495 | 1,141 | 2,895 | 2,528 | 1,059 | Upgrade |
Gross Profit | 4,787 | 4,267 | 2,338 | 1,255 | 2,319 | 5,673 | Upgrade |
Selling, General & Admin | 3,986 | 4,704 | 4,974 | 5,130 | 5,143 | 3,417 | Upgrade |
Research & Development | 6,160 | 6,828 | 6,650 | 11,941 | 12,589 | 8,860 | Upgrade |
Other Operating Expenses | 127.6 | 188.11 | 147.22 | 226.04 | 106.36 | 126.21 | Upgrade |
Operating Expenses | 11,092 | 12,714 | 12,481 | 20,086 | 19,684 | 13,705 | Upgrade |
Operating Income | -6,305 | -8,447 | -10,143 | -18,830 | -17,365 | -8,032 | Upgrade |
Interest Expense | -36.84 | -42.93 | -143.76 | -103.44 | -114.73 | -446.21 | Upgrade |
Interest & Investment Income | 323.57 | 496.33 | 68.72 | 66.8 | 115.42 | 100.29 | Upgrade |
Currency Exchange Gain (Loss) | 0.84 | 38.46 | -55.89 | 96.53 | 309.83 | -105.14 | Upgrade |
Other Non Operating Income (Expenses) | -159.68 | 1,513 | -10,922 | 138.54 | -32.11 | -1,546 | Upgrade |
EBT Excluding Unusual Items | -6,177 | -6,442 | -21,196 | -18,632 | -17,086 | -10,029 | Upgrade |
Gain (Loss) on Sale of Assets | -15.62 | -0 | 324.62 | -172.61 | 15.23 | - | Upgrade |
Pretax Income | -6,192 | -6,442 | -20,871 | -18,804 | -17,071 | -10,029 | Upgrade |
Net Income | -6,192 | -6,442 | -20,871 | -18,804 | -17,071 | -10,029 | Upgrade |
Net Income to Common | -6,192 | -6,442 | -20,871 | -18,804 | -17,071 | -10,029 | Upgrade |
Shares Outstanding (Basic) | 15 | 15 | 13 | 12 | 12 | 10 | Upgrade |
Shares Outstanding (Diluted) | 15 | 15 | 13 | 12 | 12 | 10 | Upgrade |
Shares Change (YoY) | 7.36% | 19.30% | 1.87% | 1.01% | 21.93% | 5.25% | Upgrade |
EPS (Basic) | -419.15 | -436.14 | -1667.00 | -1530.00 | -1403.00 | -1005.00 | Upgrade |
EPS (Diluted) | -499.76 | -511.00 | -1667.00 | -1530.00 | -1403.00 | -1005.00 | Upgrade |
Free Cash Flow | -3,150 | -7,003 | -7,801 | -11,193 | -16,720 | -11,745 | Upgrade |
Free Cash Flow Per Share | -213.25 | -468.82 | -623.04 | -910.72 | -1374.20 | -1177.03 | Upgrade |
Gross Margin | 80.32% | 74.05% | 67.21% | 30.25% | 47.85% | 84.27% | Upgrade |
Operating Margin | -105.78% | -146.58% | -291.53% | -453.68% | -358.23% | -119.32% | Upgrade |
Profit Margin | -103.90% | -111.78% | -599.90% | -453.06% | -352.17% | -148.98% | Upgrade |
Free Cash Flow Margin | -52.86% | -121.52% | -224.21% | -269.68% | -344.94% | -174.48% | Upgrade |
EBITDA | -4,356 | -6,409 | -7,788 | -15,869 | -15,049 | -6,563 | Upgrade |
EBITDA Margin | -73.08% | -111.21% | -223.86% | - | - | -97.49% | Upgrade |
D&A For EBITDA | 1,949 | 2,038 | 2,354 | 2,962 | 2,316 | 1,469 | Upgrade |
EBIT | -6,305 | -8,447 | -10,143 | -18,830 | -17,365 | -8,032 | Upgrade |
EBIT Margin | -105.78% | -146.58% | -291.53% | - | - | -119.32% | Upgrade |
Advertising Expenses | - | 71.25 | 55.98 | 51.34 | 101.71 | 25.33 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.